Ivacaftor is a medication used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (primarily the G551D mutation), who account for 4–5% cases of cystic fibrosis. It is also included in combination medications, lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor which are used to treat people with cystic fibrosis.
via Wikipedia infobox
via PubMed
Ivacaftor is a medication used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (primarily the G551D mutation), who account for 4–5% cases of cystic fibrosis. It is also included in combination medications, lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor which are used to treat people with cystic fibrosis.
Ivacaftor was approved by the US Food and Drug Administration (FDA) in January 2012. The combination drug lumacaftor/ivacaftor was approved by the FDA in July 2015. Ivacaftor, and the combination elexacaftor/tezacaftor/ivacaftor, are both on the World Health Organization's List of Essential Medicines.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).